Question 1

Can LL-37 peptide help with weight loss?

Accepted Answer

Among the studies behind this page, none measured body weight, fat or appetite in anyone given LL-37, and none tested it for weight in animals either. The functions that have actually been documented point somewhere else entirely. A 2017 review of defence peptides across vertebrate animals lists their roles as immune responses, wound healing, the growth of new blood vessels, neutralising toxins, iron handling and male reproduction. Weight and fat metabolism do not appear on that list. The closest link to metabolism is indirect: a 2013 review explains that changes in the production of these peptides directly influence which bacteria live in the gut. Gut bacteria have their own research story, but nothing among these sources connects LL-37 to body weight through that route. A claim that LL-37 helps with weight loss is therefore not derived from any measurement in this record. It may reflect confusion with other peptides that are studied for weight, which is a different question entirely.

Question 2

What does peptide LL-37 do?

Accepted Answer

According to the laboratory record it performs three broad jobs, and the first is killing microorganisms directly. A 2014 overview explains that LL-37 folds into a long spiral with two water-repelling regions, which allows it to bind bacterial membranes and puncture them. The second is neutralising bacterial debris, and a 2014 review notes that cathelicidins disable toxic bacterial components such as lipopolysaccharide, the outer coat material that can provoke fever and shock. The third is signalling to the immune system, where a 2004 review lists it as attracting several kinds of white blood cell to a site, altering how macrophages switch genes on, and stimulating new blood vessels and new surface skin in healing wounds. A 2022 paper adds that it functions as an alarm signal for the immune system as well as a microbe killer. Each of those describes the body's own peptide at work, and whether an external dose does the same in a person is a different question.

Question 3

How long does it take for LL-37 to work?

Accepted Answer

The studies behind this page never gave LL-37 to a person and waited, so there is no human timeline to report. What they do provide is the clock each experiment ran on, which is useful in a narrower way. In rats with eye inflammation, the effect of the precursor fragment was measured 24 hours after the injection. In laboratory biofilms of Pseudomonas, defence peptides including LL-37 produced a thousand-fold kill within 24 hours in time-kill tests. SAAP-148, a peptide engineered from LL-37, eliminated biofilm infections from wounded skin after a single four-hour treatment, both in samples of human skin kept outside the body and in mice. In the body's own response, mouse gut tissue produced three times more cathelicidin after surgery that leaks gut bacteria, peaking at 4 hours. These are windows of hours in tightly controlled experimental settings. They describe how quickly a peptide acts on bacteria directly in front of it, rather than how long a person would wait to notice anything.

Question 4

Does LL-37 help wounds heal?

Accepted Answer

In mice, yes, on the two specific measurements that were taken. A 2011 study used mice given dexamethasone, a steroid that slows wound repair, so that any improvement would be readily detectable. Applied to the wounds, both synthetic and laboratory-grown LL-37 increased new blood vessel growth and the regrowth of surface skin in those mice. In cell experiments from the same study, the peptide made the cells lining blood vessels multiply, migrate and form tube-like structures. Wound healing is also the application most frequently claimed in patents, and a 2010 review of patent filings lists LL-37 and its derivatives for exactly that purpose. In people, the closest available evidence is indirect. Skin cells from a severe inherited blistering disease produced too little hCAP18, and calcipotriol, a vitamin D-like ingredient of skin creams, restored it in cell culture; the authors also describe a single patient observed on it. A patent filing and one patient are not the same as a controlled trial.

Question 5

Does LL-37 calm inflammation?

Accepted Answer

Sometimes, in animals and cells, when the inflammation is driven by bacterial toxin. In a 2003 rat study, eye inflammation was provoked by injecting lipopolysaccharide, a fragment of bacterial coat, into a footpad. A 27-unit piece from the end of hCAP18, the protein LL-37 is cut from, was then injected into a vein. At 10 and 100 micrograms it suppressed the rise in inflammatory cells and several inflammatory signals in the rats' eye fluid. The authors propose that it works by binding the toxin directly. In a 2011 study, a laboratory-made LL-37 neutralised the activation of macrophages by the same toxin in cell culture. That is a genuine anti-inflammatory signal, but a narrow one: it covers inflammation started by bacterial coat material. In psoriasis, rosacea and a mouse heart model, the body's own LL-37 sits on the opposite side of the ledger, feeding inflammation rather than damping it, and the LL-37 safety page sets out that evidence.

Question 6

Has LL-37 protected a living animal from infection?

Accepted Answer

The strongest animal evidence concerns the mouse's own cathelicidin, not LL-37 given as a dose. A 2001 study showed that cathelicidins form an important part of natural defence in mice, protecting them against a flesh-destroying skin infection with group A streptococcus. A 2020 mastitis study found the same pattern in the breast: mice lacking the gene, once infected with Staphylococcus aureus, carried more bacteria and developed more severe disease. That study also tested peptide from outside. Synthetic human LL-37 and synthetic mouse CRAMP, both at 8 micromolar, reduced how far the bacteria invaded mouse breast lining tissue. A third mouse study found that an experimental gonorrhoea compound stopped working in mice without cathelicidin. Knockout results reveal what the body's own supply contributes, whereas only the mastitis work tested the human peptide from outside, and it measured invasion into tissue rather than recovery from illness.

Question 7

Does LL-37 help antibiotics clear biofilms?

Accepted Answer

In the lab, LL-37 can help antibiotics work better against biofilms, the slimy bacterial communities that resist ordinary antibiotics. A 2014 study grew these films from one lab strain of Pseudomonas and four strains taken from patients. Adding LL-37 at a tenth of the amount it needed to clear the film on its own reduced the antibiotic concentration required by up to eightfold in vitro, meaning in glassware. Used alone, by contrast, the antimicrobial peptides needed at least 640 milligrams per litre to eradicate a biofilm. Other comparisons are considerably less flattering to the natural peptide. A 2019 study measured how much each peptide boosted two antibiotics against drug-resistant Pseudomonas, and its own new peptides gave a much greater joint effect than LL-37 did. A 2017 study found that many ceragenins, man-made mimics of these peptides, broke up the films more strongly than LL-37 did. All of this is laboratory work, and it shows that LL-37 has a measurable partnering effect with antibiotics, which does not mean the combination helps an infected person.

Question 8

Does LL-37 protect the gut lining?

Accepted Answer

In mice, the body's own version apparently does. A 2020 sepsis study compared normal mice with mice lacking the cathelicidin gene after surgery that lets gut bacteria leak into the abdomen. Without the gene, significantly more mice died within seven days. Their intestinal wall also became leakier, letting a tracer dye pass through more easily, with less of the proteins that seal the gaps between lining cells. The authors conclude that the mouse's own cathelicidin supports the integrity of the gut barrier. A 2015 mouse paper begins from the same premise, that LL-37 and the mouse peptide can protect animals against a failing gut barrier, although what it then tested was a cathelicidin from snake venom, a different molecule again. Microbes appear to target this defence too: a 2013 review notes that Shigella, a cause of dysentery, suppresses the gut's production of LL-37. None of these experiments gave LL-37 by mouth or injection, so it describes a natural defence rather than a usable one.

Question 9

Does LL-37 matter for gums, teeth and bone?

Accepted Answer

This is where the research is most active, and almost all of it regards LL-37 as something to measure or to steer rather than to administer. A 2014 review explains that bacterial products trigger both bone-dissolving cells and cathelicidin production, and that cathelicidins can then suppress the formation of those bone-dissolving cells. Its authors discuss LL-37 as a pharmaceutical target against inflammation and bone loss in gum disease. A 2021 review of dental pulp research concludes that LL-37 plays an important role in forming reparative dentine, the tissue a tooth lays down after damage. On the human side, two completed registry entries measure LL-37 during gum disease care and around dental implants, with 60 and 33 people enrolled. Measuring a marker is different from using it as a remedy. The bone story also has a second edge: at concentrations the body can reach, LL-37 harmed bone-forming cells in culture, as the LL-37 safety page describes.

Question 10

What has LL-37 been studied for in people?

Accepted Answer

As a reading on a laboratory test rather than as a remedy, since in the studies covered here people appear because their own LL-37 was measured. A completed registry study of 60 people examined how smoking and vitamin D3 affect LL-37 levels. A 2014 review of infected joint replacements lists cathelicidin LL-37 in joint fluid among the more specific markers for diagnosing an infected implant. The most interesting human result runs through skin bacteria: a 2017 study found that helpful staphylococcal strains on healthy skin make their own antimicrobial peptides that act together with LL-37, and that these strains are rare on people with eczema. Reintroducing the strains to patients with atopic dermatitis reduced colonisation by Staphylococcus aureus. What those patients received was bacteria, not LL-37, so the human record studies the peptide as a marker and as a partner, and the question of giving it to a person has not been asked in this record.

Question 11

Does a benefit in one condition carry to another?

Accepted Answer

Not reliably, and the mouse research illustrates exactly why. The same family of peptide that protected mouse skin from streptococcal infection made mouse heart injury worse when it was given before blood flow returned to a blocked artery. In the heart study, mice lacking the gene did better; in the skin and breast studies, mice lacking it did worse. One molecule produced opposite consequences depending on the tissue involved. There is a species gap on top of that, because the mouse peptide, CRAMP, and human LL-37 come from similar genes and have similar shapes, ranges of activity and tissue distribution, which is why mice are used, but they are not the same molecule. A 2000 review warned that animal model systems may sometimes invite misinterpretation. A 2001 paper also noted that the protective role of these peptides had been questioned because several are easily inactivated in the body. A benefit in one setting is a reason to test another, rather than a result for it.

Question 12

Do peptides built from LL-37 work better than LL-37?

Accepted Answer

On the measures their designers chose, yes, and that is the direction the field has taken. A 2018 team built a set of new peptides from LL-37 that killed germs more strongly than the parent did. Their lead candidate, SAAP-148, killed drug-resistant bacteria without the bacteria developing resistance in laboratory tests. A 2025 group selected an eight-unit segment of LL-37, FFRKSKEK, that becomes active under ultrasound. In goats with a stubborn infection of the spinal discs, the peptide combined with ultrasound outperformed vancomycin, a standard antibiotic. A third team fused a fragment of LL-37 with pieces of other species' peptides, and one hybrid had the strongest effect and the best aim at bacteria rather than host cells. These results belong to the new molecules, and they are not evidence about LL-37 itself, and each was engineered precisely because the original had shortcomings.

Question 13

Is every LL-37 effect a benefit?

Accepted Answer

No, and a benefits page that omitted this would be misleading. The same signalling capacity that attracts immune cells to a wound can also perpetuate inflammation. A 2022 paper focuses on how LL-37 acts directly on neutrophils and their release of DNA webs, which defend against microbes but also contribute to chronic disease and tissue damage. A 2015 review of smoking-related lung disease lists LL-37 among the molecules found in higher quantities in the lungs of smokers with ongoing inflammation. In acne lesions, a 2014 study of patient biopsies found hCAP18 switched on alongside the IL-17 pathway that drives the inflammation. Higher levels in diseased tissue do not prove that LL-37 causes the damage, but they sit beside the psoriasis, rosacea and mouse heart findings as reasons to weigh the upside carefully. The full account of those findings is on the LL-37 safety page.

Question 14

What would it take to show a benefit in a person?

Accepted Answer

It would take a trial that gave LL-37 itself to people and compared them with people who did not receive it, and none of the studies behind this page did that. The shape of such a study is visible in this record, aimed at something else. A 2013 kidney trial gave high-dose vitamin D or a matching placebo for a year, in a double-blind, randomised design, and checked blood cathelicidin along the way. A trial of the peptide would need the same structure, a defined condition, and an outcome a patient would genuinely notice, such as a wound closing or an infection resolving. It would also need a form that survives in the body, since a 2025 paper notes that natural antimicrobial peptides can be rapidly broken down. A 2019 review sees human defence peptides as promising tools against viruses that lack approved vaccines or treatments, which is a statement of promise rather than of results. Until such a trial exists, every benefit on this page remains an animal or laboratory measurement.

LL-37: what the research measured